MGRM Monogram Technologies Inc

- Additional Intellectual Property Portfolio to Expand and Strengthen Caliper Driven(TM) Licensing Program - HOPKINTON, Mass. and SOUTH SAN FRANCISCO, Calif., May 2 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (NASDAQ:CALP) and Monogram Biosciences, Inc. (NASDAQ:MGRM), today announced an agreement under which Monogram has licensed most of its microfluidics patent portfolio to Caliper on an exclusive basis. The intellectual property licensed to Caliper originates from ACLARA BioSciences, which merged with Monogram in December of 2004. Financial terms of the agreement were not disclosed. Caliper, a pioneer in the development and commercialization of microfluidics, continues to seek opportunities to maximize the commercialization of this technology and more fully exploit its advantages for drug discovery and diagnostic applications. Through the agreement with Monogram, Caliper has created the most comprehensive, unrivaled microfluidics patent estate, further solidifying the company's Caliper Driven licensing program. With the addition of the patents exclusively licensed from Monogram, the Caliper patent estate available for licensing under the Caliper Driven program now includes more than 335 United States patents. "Microfluidics technology is gaining main-stream market adoption. It is a next-generation experimentation platform offering unprecedented data quality, workflow integration and scalability for critical research and diagnostic applications," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "By incorporating Monogram's microfluidic patent estate into our own, we are able to expand the overall breadth and versatility of the applications that we can now pursue -- either on our own or with partners through our Caliper Driven program." "Caliper is the undisputed leader in developing the power of microfluidics," said Michael Dunn, chief business officer of Monogram Biosciences. "Given this leadership position, we see many advantages to combining our microfluidics intellectual property with Caliper's commercialization engine to further exploit the power of this innovative technology." Microfluidic technology represents a revolution in laboratory experimentation, bringing the benefits of miniaturization, integration and automation to many research-based industries. Currently, 18 of the top 20 pharmaceutical companies, including AstraZeneca, Novartis and Vertex, along with a growing number of biotechnology and research institutions use Caliper's microfluidic-based LabChip(R) systems. Caliper has also partnered with companies such as Affymetrix, Agilent Technologies, Bio-Rad Laboratories, Canon U.S. Life Sciences and Wako Pure Chemicals to further develop and commercialize LabChip-based solutions. Under the terms of the license agreement, Monogram retains the right to practice the licensed microfluidics intellectual property for use with its proprietary eTag(TM) technology. About Caliper Life Sciences Caliper Life Sciences is a leading provider of drug discovery and life sciences research solutions for the pharmaceutical and biotechnology industries. With its acquisitions of NovaScreen Biosciences and Xenogen Corporation, Caliper has positioned itself to transform drug discovery and development through a keen focus on clinically relevant experimentation. Caliper's products and services, assembled from a leading portfolio of microfluidics, liquid handling, and imaging technologies, span in vitro and in vivo experimentation and address key issues on the critical path of drug discovery and development. More information about Caliper can be found at http://www.caliperls.com/. About Monogram Biosciences, Inc. Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com/. The statements in this press release regarding future events, including statements regarding Caliper's and Monogram's plans to maximize the commercialization of microfluidic technology through the combination of their microfluidic patent estates and to more fully exploit the advantages of microfluidic technology for drug discovery and diagnostic applications, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statement as a result of a number of factors, including the risk that unexpected difficulties may be encountered in developing new products based on microfluidic technology or in gaining wide commercial adoption of any newly developed products. Further information on risks faced by Caliper with respect to its microfluidic technology are detailed under the caption "Risks Related To Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2006. Further information on risks faced by Monogram with respect to its microfluidic intellectual property are detailed in the "Risk Factors" section of Monogram's Annual Report on Form 10-K for the year ended December 31, 2006. These filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov/. Caliper and Monogram do not undertake any obligation to update forward-looking or other statements in this release. NOTE: LabChip is a registered trademark, and Caliper Driven is a trademark, of Caliper Life Sciences, Inc. eTag is a trademark of Monogram Biosciences, Inc. DATASOURCE: Caliper Life Sciences, Inc. CONTACT: Stacey Holifield, or Melissa Bruno, both of Schwartz Communications, +1-781-684-0770, for Caliper Life Sciences; or Jeremiah Hall of Feinstein Keane, +1-415-677-2720, for Monogram Biosciences Web site: http://www.monogrambio.com/ Web site: http://www.caliperls.com/

Copyright